Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events.

ABSTRACT:

Objective

A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with imatinib report skeletomuscular adverse events affecting their quality of life. OCTN2 membrane transporter is involved in imatinib transportation into the cells. At the same time, the crucial physiological role of OCTN2 is cellular uptake of carnitine which is an essential co-factor for the mitochondrial β-oxidation pathway. This work investigates the impact of imatinib treatment on carnitine intake and energy metabolism of muscle cells.

Methods

HTB-153 (human rhabdomyosarcoma) cell line and KCL-22 (CML cell line) were used to st

SUBMITTER: Burda P 

PROVIDER: S-EPMC11403060 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature